Mesoblast Ltd Sustainability Reports
Mesoblast Limited is a global leader in developing innovative cell-based medicines and regenerative medicine therapies. The company utilizes its proprietary adult stem cell platform to establish late-stage product candidates for inflammatory diseases, cardiovascular conditions, and orthopedic disorders.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
LEI: 529900J5ALF3JG921927
FIGI: BBG001SFQM79
16 reports from 2008 to 2025
